HOME >> BIOLOGY >> NEWS
Case Western Reserve University licenses methoxyamine to Tracon

CLEVELAND--Case Western Reserve University's Technology Transfer Office has entered a worldwide exclusive licensing agreement with TRACON Pharmaceuticals of San Diego, Calif., to develop Methoxyamine, a new cancer therapeutic that reverses cancer cell resistance to chemotherapy. Methoxyamine is a "first in class" drug that targets a specific DNA repair pathway.

TRACON Pharmaceuticals is an emerging biotechnology company focused on identifying, developing and commercializing targeted therapies for cancer and angiogenesis. TRACON's management team couples their ability to execute with their extensive knowledge of oncology drug development and first generation targeted therapies, enabling them to advance the development of next generation cancer therapies.

Methoxyamine was developed by University Hospitals Case Medical Center researchers Stanton Gerson, M.D., director of the National Cancer Institute-designated Case Comprehensive Cancer Center and University Hospitals Ireland Cancer Center, and Lili Lui, Ph.D., assistant professor of medicine in the department of hematology and oncology at the Case School of Medicine. They were the first to show the therapeutic potential of Methoxyamine as an anti-cancer drug in combination with other agents.

"We are very excited about the potential of this new drug. The promise of overcoming a major mechanism of drug resistance in cancer is terrific news for many patients. We see potential applications in patients with brain cancers, melanoma, lung cancer and leukemias and perhaps other cancers," said Gerson.

Under the licensing agreement, TRACON will develop and manage clinical trials of Methoxyamine. "We are excited to be able to develop Methoxyamine. Chemotherapy represents the most commonly used class of agents to treat cancer patients. Unfortunately, resistance of cancer cells to chemotherapy prevents many patients from benefiting. Methoxyamine's unique ability to reverse res
'"/>

Contact: Susan Griffith
susan.griffith@case.edu
216-368-1004
Case Western Reserve University
13-Oct-2006


Page: 1 2

Related biology news :

1. Study finds Western-style meat-sweet diet increases risk of breast cancer in postmenopausal women
2. Case Western Reserve University School of Medicine researchers awarded $27M for TB research
3. Case Western researcher, international team call for better global warming forecasting
4. WHSRN awarded major grant to foster shorebird conservation throughout the Western Hemisphere
5. Case Western Reserve University biologists suspect lightning fires help preserve oak forests
6. Case Western Reserve University chemist takes on HIV-1 virus with $1M support from NIH
7. Case Western Reserve University paleontologist discovers South American mammal fossils
8. Case Western Reserve University researchers find protein associated with brain cell death
9. In Western bluebird as well as human families, accumulated wealth encourages stability
10. Case Western Reserve University School of Medicine gets $4 million to make smart nanoparticles
11. ASU students host first annual Western Regional Bioethics Conference

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Case Western Reserve University licenses methoxyamine Tracon

(Date:6/25/2015)... June 25, 2015 According ... Type (Swipe & Area), Technology, Material (Optical Prism, ... Commercial Security & Others) & Geography - Global ... the said market is expected to reach $14,500.07 ... Browse 76 market Tables and ...
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., a ... by the United States Patent and Trademark Office (USPTO) ... process leverages TAKE Solutions, Clinical Accelerators to reduce the ... (when compared to standardization without the accelerators), thus reducing ... At the heart of the patented ...
(Date:6/24/2015)... June 24, 2015 This report provides market ... next six years. It contains an analysis of the ... with their impact from the short, medium, and long ... the industry, market, and technology trends that currently, prevail ... of concerned authorities to efficiently manage the increasing marine ...
Breaking Biology News(10 mins):Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
(Date:7/29/2015)... TX (PRWEB) , ... July 29, 2015 , ... ... designer, manufacturer and supplier, announces the launch of their 2nd generation cell therapy ... the current miniPOD CT, but it also represents a new POD® design. ...
(Date:7/29/2015)... 2015  AmnioChor Inc., an early stage biotech startup ... to announce that the Musculoskeletal Transplant Foundation of ... in their seed round of development of the proprietary ... AmnioChor,s technology allows cryopreservation of the ... cells living within those tissues. Amnion is a well-established ...
(Date:7/29/2015)...  Indivior PLC (LON: INDV) today announced that the ... accepted and received Priority Review by the U.S. Food ... overdose. This naloxone nasal spray comes as a pre-filled ... into the nasal mucosa. 1 The device has ... be better equipped to help an opioid overdose victim. ...
(Date:7/29/2015)... QUEBEC CITY , July 29, 2015 /PRNewswire/ ... (the "Company") today announced it has selected an optimized ... important milestone in the development of a new ... The MAPK pathway represents a prime target for ... significant antitumor activities and survival benefits for B-Raf ...
Breaking Biology Technology:G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3
Cached News: